News
Roche gets fast FDA review for Tecentriq in adjuvant lung ca...
Roche is preparing for a December verdict from the FDA on adjuvant use of its PD-L1 inhibitor Tecentriq as an adjuvant treatment for some patients with non-small cell lung cancer (NSCLC).
